摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-甲基-4-硝基-2-氰基吡啶 | 30235-12-2

中文名称
6-甲基-4-硝基-2-氰基吡啶
中文别名
6-甲基-4-硝基吡啶-2-甲腈
英文名称
6-methyl-4-nitropyridine-2-carbonitrile
英文别名
6-methyl-4-nitropicolinonitrile
6-甲基-4-硝基-2-氰基吡啶化学式
CAS
30235-12-2
化学式
C7H5N3O2
mdl
MFCD09839154
分子量
163.136
InChiKey
VITXYPUCOQUWPJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    74-79 °C

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.142
  • 拓扑面积:
    82.5
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    T
  • 安全说明:
    S26,S39,S45
  • 危险类别码:
    R25
  • WGK Germany:
    3
  • 海关编码:
    2933399090
  • 危险品运输编号:
    UN 2811 6.1/PG 3
  • 储存条件:
    -20°C,密封保存,并保持干燥。

SDS

SDS:fd3f52d709e217ba2e0a8e96a7fee933
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 6-Methyl-4-nitropyridine-2-carbonitrile
CAS-No. : 30235-12-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 3)
Skin irritation (Category 2)
Serious eye damage (Category 1)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Toxic if swallowed. Irritating to respiratory system and skin. Risk of serious damage to eyes.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H315 Causes skin irritation.
H318 Causes serious eye damage.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P280 Wear protective gloves/ eye protection/ face protection.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R25 Toxic if swallowed.
R37/38 Irritating to respiratory system and skin.
R41 Risk of serious damage to eyes.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S39 Wear eye/face protection.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 2-Cyano-6-methyl-4-nitropyridine
6-Methyl-4-nitropicolinonitrile
Formula : C7H5N3O2
Molecular Weight : 163,13 g/mol
Component Concentration
6-Methyl-4-nitropyridine-2-carbonitrile
CAS-No. 30235-12-2 -

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate
ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas.
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 74 - 79 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 0,396
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals. The
preceding data, or interpretation of data, was determined using Quantitative Structure Activity Relationship
(QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion Toxic if swallowed.
Skin
May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes eye burns.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (6-Methyl-4-nitropyridine-2-carbonitrile)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (6-Methyl-4-nitropyridine-2-carbonitrile)
IATA: Toxic solid, organic, n.o.s. (6-Methyl-4-nitropyridine-2-carbonitrile)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-甲基-4-硝基-2-氰基吡啶硫酸 、 sodium nitrite 作用下, 生成 6-甲基-4-硝基吡啶-2-羧酸
    参考文献:
    名称:
    含有取代的吡啶羧酸盐螯合配体的烃基钯(II)配合物的羰基化。CO插入机制的立体和电子操纵
    摘要:
    通式[PdR(N–O)L]的有机钯(II)配合物[R = Ph,N–O =吡啶羧酸盐(pyca),L = P(C 6 H 11)3;R = Ph,N–O = 6-甲基吡啶甲酸甲酯(mpyca),L = PPh 3,PMePh 2,P(C 6 H 11)3或PEt 3;R = Ph,N–O = 4-硝基吡啶羧酸盐(npyca),L = P(C 6 H 11)3;R = Ph,N–O = 6-甲基-4-硝基吡啶甲酸甲酯,L = P(C 6 H 11)3;R = Me,N–O = mpyca,L = PPh 3,P(CH 2 Ph)3或P(C 6 H 11) 3;制备了R = Me,N–O = npyca,L = PPh 3,PMePh 2或P(C 6 H 11) 3 ],并对其羰基化反应进行了详细的研究。CO插入过程的动力学研究表明,反应速率随着膦L的碱度的增加而降低。含有高碱性膦P(C 6 H
    DOI:
    10.1039/dt9960002197
  • 作为产物:
    描述:
    参考文献:
    名称:
    含有取代的吡啶羧酸盐螯合配体的烃基钯(II)配合物的羰基化。CO插入机制的立体和电子操纵
    摘要:
    通式[PdR(N–O)L]的有机钯(II)配合物[R = Ph,N–O =吡啶羧酸盐(pyca),L = P(C 6 H 11)3;R = Ph,N–O = 6-甲基吡啶甲酸甲酯(mpyca),L = PPh 3,PMePh 2,P(C 6 H 11)3或PEt 3;R = Ph,N–O = 4-硝基吡啶羧酸盐(npyca),L = P(C 6 H 11)3;R = Ph,N–O = 6-甲基-4-硝基吡啶甲酸甲酯,L = P(C 6 H 11)3;R = Me,N–O = mpyca,L = PPh 3,P(CH 2 Ph)3或P(C 6 H 11) 3;制备了R = Me,N–O = npyca,L = PPh 3,PMePh 2或P(C 6 H 11) 3 ],并对其羰基化反应进行了详细的研究。CO插入过程的动力学研究表明,反应速率随着膦L的碱度的增加而降低。含有高碱性膦P(C 6 H
    DOI:
    10.1039/dt9960002197
点击查看最新优质反应信息

文献信息

  • Monoacylglycerol Lipase Modulators
    申请人:Janssen Pharmaceutica NV
    公开号:US20200102311A1
    公开(公告)日:2020-04-02
    Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R 2 , R 3 R 4 , R 5 and R 6 are defined herein.
    桥接化合物,其结构式为(I)和(II),包含它们的药物组合物,制造它们的方法,以及使用它们的方法,包括用于治疗与MGL调节相关的疾病状态、障碍和状况的方法,如与疼痛、精神障碍、神经障碍(包括但不限于重性抑郁障碍、难治性抑郁、焦虑性抑郁、双相情感障碍)、癌症和眼科疾病相关的方法。 其中R2、R3、R4、R5和R6的定义如下。
  • 4-Aryl-pyridine-2-carboxyamide derivatives
    申请人:Jaeschke Georg
    公开号:US20070197553A1
    公开(公告)日:2007-08-23
    The present invention relates to novel pyridine-2-carboxyamide derivatives of formula (I) useful as metabotropic glutamate receptor antagonists: wherein Y, Z, R 1 , R 2 and R 3 are as defined in the specification herein.
    本发明涉及一种新型吡啶-2-羧酰胺衍生物,其化学式为(I),可用作代谢型谷氨酸受体拮抗剂: 其中Y、Z、R1、R2和R3如本说明书中所定义。
  • [EN] 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO<br/>[FR] DERIVES DE 1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO-2,3-C PYRIDIN-2-YLMETHYL)PENTAN-2-OLE ET COMPOSES ASSOCIES EN TANT QUE LIGANDS DE GLUCOCORTICOIDES POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES ET DE DIABETE
    申请人:BOEHRINGER INGELHEIM PHARMA
    公开号:WO2005030213A1
    公开(公告)日:2005-04-07
    Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    式(I A)、(IB)、(IC)和(ID)的化合物,其中R1、R2、R3、R4、R5和R6分别如本文所定义的式(I A)、(IB)、(IC)和(ID),或其互变异构体、前药、溶剂化合物或盐;含有这些化合物的药物组合物,以及利用这些化合物调节糖皮质激素受体功能的方法,以及利用这些化合物治疗由糖皮质激素受体功能介导或以炎症、过敏或增殖过程为特征的疾病状态或病情的方法。
  • [EN] SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] DÉRIVÉS DE SULFAMOYLPYRROLAMIDE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE L'HÉPATITE B
    申请人:JANSSEN SCIENCES IRELAND UC
    公开号:WO2015118057A1
    公开(公告)日:2015-08-13
    Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    HBV复制的Formula(A)的抑制剂包括立体化学异构体形式,以及它们的盐、水合物、溶剂合物,其中Ra到Rd和R5到R6具有本文所定义的含义。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HBV治疗中的单独使用或与其他HBV抑制剂联合使用。
  • N-(phenylsulfonyl)picolinamide derivatives, process for producing the same, and herbicide
    申请人:Kureha Kagaku Kogyo K.K.
    公开号:US06610853B1
    公开(公告)日:2003-08-26
    A herbicide containing as the active ingredient an N-(henylsulfonyl)picolinamide derivative represented by general formula (I) wherein X reprcsents a halogeno, a C1-4 alkyl, a C1-4 haloalkyl, a C1-4 alkoxy, a C1-4 haloalkoxy, a (C1-4 alkoxy)carbonyl, a [di(C1-4 alkyl)amino]sulfonyl, an [N—(C1-4 alkyl)-N—(C1-4 alkoxy)amino]sulfonyl, a (C1-4 alkylamino)sulfonyl, a C1-4 alkylthio, a C1-4 alkylsulfinyl, a C1-4 alkylsulfonyl, or nitro; n is an integer of 0 to 5; Y represets a halogeno, a C1-4 alkyl, a C1-4 haloalkyl, a C1-4 alkoxy, C1-4 haloalkoxy, a C1-4 alkylthio, a C1-4 haloalkylthio, amino, a C1-4 alkylamino, a di(C1-4 alkyl)amino, a (C1-4 alkoxy) C1-4 alkyl, a (C1-4 alkylthio) C1-4 alkyl, or nitro; and m is an integer of 0 to 4. This active ingredient is synthesized by condensing a substituted picolinic acid with a substituted benzenesulfonamide under dehydration, or by reacting the phenyl ester of a substituted picolinic acid with a substituted benzenesulfonamide in the presence of a basic compound.
    一种除草剂,其活性成分为一种由通式(I)表示的N-(苯基磺酰基)吡啶甲酰胺衍生物,其中X代表卤素、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基、(C1-4烷氧基)羰基、[二(C1-4烷基)氨基]磺酰基、[N-(C1-4烷基)-N-(C1-4烷氧基)氨基]磺酰基、(C1-4烷基氨基)磺酰基、C1-4烷基硫醚、C1-4烷基亚砜基、C1-4烷基磺酰基或硝基;n为0至5的整数;Y代表卤素、C1-4烷基、C1-4卤代烷基、C1-4烷氧基、C1-4卤代烷氧基、C1-4烷基硫醚、C1-4卤代烷基硫醚、氨基、C1-4烷基氨基、二(C1-4烷基)氨基、(C1-4烷氧基)C1-4烷基、(C1-4烷基硫醚)C1-4烷基或硝基;m为0至4的整数。该活性成分通过将取代吡啶甲酸与取代苯磺酰胺在脱水条件下缩合合成,或者在碱性化合物存在下,将取代吡啶甲酸的苯酯与取代苯磺酰胺反应而制备。
查看更多